Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells

International Journal of Cancer

Volumn 104, Issue 6, 2003, Pages 683-694

  Truant, Stéphanie ^a,c   Bruyneel, Erik ^b   Gouyer, Valérie ^a   De Wever, Olivier ^b   Pruvot, François René ^c   Mareel, Mark ^b   Huet, Guillemette ^a  

^a INSERM   (France)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Colon carcinoma cells; E cadherin; Heparan sulfate proteoglycans; Mucins

Indexed keywords

COLLAGEN TYPE 1; MUCIN; MUCIN 1; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; PYRANOSIDE; UVOMORULIN; XYLOSE;

ARTICLE; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CELL INTERACTION; COLON CARCINOMA; CONTROLLED STUDY; DISSOCIATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNET RING CARCINOMA;

BLOTTING, WESTERN; CA-15-3 ANTIGEN; CADHERINS; CELL ADHESION; CELL AGGREGATION; COLLAGEN; DNA PRIMERS; GALACTOSE; GLYCOSIDES; HT29 CELLS; HUMANS; MICROSCOPY, CONFOCAL; MUCINS; NEOPLASM INVASIVENESS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0345269741     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11011     Document Type: Article

References (53)

1. Gumbiner B, Stevenson B, Grimaldi A. The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J Cell Biol 1988;107:1575-87.
2. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-11. Review.
3. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108:2435-47.
4. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/betacatenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993;120:757-66.
5. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, Van de Vijver M, Cornelisse C, Van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14: 6107-15.
6. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
7. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001;439:725-51. Review.
8. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19.
9. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995;71:614-6.
10. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Betacatenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997;94:10330-4.
11. Munemitsu S, Albert I, Rubinfeld B, Polakis P. Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol Cell Biol 1996;16:4088-94.
12. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
13. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
14. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998;18:7216-24.
15. Wesseling J, Van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:565-77.
16. Steelant WF, Goeman JL, Philippe J, Oomen LC, Hilkens J, Krzewinski-Recchi MA, Huet G, Van Der Eycken J, Delannoy P, Bruyneel EA, Mareel MM. Alkyl-lysophospholipid 1-O-octadecyl-2-O-methylglycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro. Int J Cancer 2001;92:527-36.
17. Vleminckx KL, Deman JJ, Bruyneel EA, Vandenbossche GM, Keirsebilck AA, Mareel MM, Van Roy FM. Enlarged cell-associated proteoglycans abolish E-cadherin functionality in invasive tumor cells. Cancer Res 1994;54:873-7.
18. Aoki R, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998;41:1262-72.
19. Li Y, Kufe D. The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun 2001;281:440-3.
20. Matsuda K, Masaki T, Watanabe T, Kitayama J, Nagawa H, Muto T, Ajioka Y. Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. Jpn J Clin Oncol 2000; 30:89-94.
21. Bara J, Gautier R, Mouradian P, Decaens C, Daher N. Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 1991;47:304-10.
22. Bara J, Chastre E, Mahiou J, Singh RL, Forgue-Lafitte ME, Hollande E, Godeau F. Gastric M1 mucin, an early oncofetal marker of colon carcinogenesis, is encoded by the MUC5AC gene. Int J Cancer 1998;75:767-73.
23. Sylvester PA, Myerscough N, Warren BF, Carlstedt I, Corfield AP, Durdey P, Thomas MG. Differential expression of the chromosome 11 mucin genes in colorectal cancer. J Pathol 2001;195:327-35.
24. Lesuffleur T, Kornowski A, Augeron C, Dussaulx E, Barbat A, Laboisse C, Zweibaum A. Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation. Int J Cancer 1991;49:731-7.
25. Lesuffleur T, Violette S, Vasile-Pandrea I, Dussaulx E, Barbat A, Muleris M, Zweibaum A. Resistance to high concentrations of methotrexate and 5-fluorouracil of differentiated HT-29 colon-cancer cells is restricted to cells of enterocytic phenotype. Int J Cancer 1998;76: 383-92.
26. Bracke ME, Vyncke BM. Bruyneel EA, Vermeulen SJ, De Bruyne GK, Van Larebeke NA, Vleminckx K, Van Roy FM, Mareel MM. Insulin-like growth factor I activates the invasion suppressor function of E-cadherin in MCF-7 human mammary carcinoma cells in vitro. Br J Cancer 1993;68:282-9.
27. Norum LF, Varaas T, Kierulf B, Nustad K. Carcinoma-associated MUC1 detected by immunoradiometric assays. Tumour Biol 1998; 19:134-46.
28. Carlstedt I, Herrmann A, Hovenberg H, Lindell G, Nordman H, Wickstrom C, Davies JR. "Soluble" and "insoluble" mucins: identification of distinct populations. Biochem Soc Trans 1995;23:845-51.
29. Fogh J and Trempe G (1975). New human tumor cell lines. In: J. Fogh, ed. Human tumor cells in vitro. New York: Plenum Press. 1975. 115-141.
30. Bracke M, Boterberg T, Mareel M. Collagen invasion assay, chick heart invasion assay. In: S. Brooks S, Schumacher U, eds. Metastasis methods and protocols. Totowa: Humana Press. 2000.
31. Boterberg, Bracke ME, Bruyneel CA, Mareel M. Cell aggregation assay. In: Brooks S, Schumacher U, eds. Metastasis methods and protocols. Totowa: Humana Press. 2000.
32. Debailleul V, Laine A, Huet G, Mathon P, d'Hooghe MC, Aubert JP, Porchet N. Human mucin genes MUC2, MUC3, MUC4, MUC5AC, MUC5B, and MUC6 express stable and extremely large mRNAs and exhibit a variable length polymorphism: an improved method to analyze large mRNAs. J Biol Chem 1998;273:881-90.
33. Contreras HR, Fabre M, Granes F, Casaroli-Marano R, Rocamora N, Herreros AG, Reina M, Vilaro S. Syndecan-2 expression in colorectal cancer-derived HT-29 M6 epithelial cells induces a migratory phenotype. Biochem Biophys Res Commun 2001;286:742-51.
34. Molist A, Romaris M, Lindahl U, Villena J, Touab M, Bassols A. Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem 1998;254:371-7.
35. Molist A, Romaris M, Villena J, Bassols A. Enterocytic differentiation correlates with changes in the fine structure and sulfation of perlecan in HT29 human colon carcinoma cells. Biochem Biophys Res Commun 1997;238:874-9.
36. Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists: cancer committee. Arch Pathol Lab Med 2000;124:1016-25.
37. Kitamura H, Cho M, Lee BH, Gum JR, Siddiki BB, Ho SB, Toribara NW, Lesuffleur T, Zweibaum A, Kitamura Y, Yonezawa S, Kim YS. Alteration in mucin gene expression and biological properties of HT29 colon cancer cell sub-populations. Eur J Cancer 1996;32A: 1788-96.
38. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, Pignatelli M, Bodmer WF. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA 1999;96:2316-21.
39. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
40. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31: 558-65.
41. Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, Hoznek A, Bastuji-Garin S, Abbou CC, Thiery JP, Radvanyi F, Chopin DK. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000;83: 209-14.
42. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 1999;81:1392-7.
43. Guyonnet Duperat V, Audie JP, Debailleul V, Laine A, Buisine MP, Galiegue-Zouitina S, Pigny P, Degand P, Aubert JP, Porchet N. Characterization of the human mucin gene MUC5AC: a consensus cysteine-rich domain for 11p15 mucin genes? Biochem J 1995;305: 211-9.
44. Julian J, Carson DD. Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. Biochem Biophys Res Commun 2002;293:1183-90.
45. Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992;52:2318-24.
46. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A. Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun 2001;283:715-20.
47. Wreschner DH, McGuckin MA, Williams SJ, Baruch A, Yoeli M, Ziv R, Okun L, Zaretsky J, Smorodinsky N, Keydar I, Neophytou P, Stacey M, et al. Generation of ligand-receptor alliances by "SEA" module-mediated cleavage of membrane-associated mucin proteins. Protein Sci 2002;11:698-706.
48. Bresalier RS, Niv Y, Byrd JC, Duh QY, Toribara NW, Rockwell RW, Dahiya R, Kim YS. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991;87:1037-45.
49. Gouyer V, Leteurtre E, Zanetta JP, Lesuffleur T, Delannoy P, Huet G. Inhibition of the glycosylation and alteration in the intracellular trafficking of mucins and other glycoproteins by GalNAcalpha-O-bn in mucosal cell lines: an effect mediated through the intracellular synthesis of complex GalNAcalpha-O-bn oligosaccharides. Front Biosci 2001;6:D1235-44. Review.
50. Hennebicq-Reig S, Lesuffieur T, Capon C, De Bolos C, Kim I. Moreau O, Richet C, Hemon B, Recchi MA, Maes E, Aubert JP, Real FX, et al. Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion. Biochem J 1998;334:283-95.
51. Huet G, Hennebicq-Reig S, de Bolos C, Ulloa F, Lesuffieur T, Barbat A, Carriere V, Kim I, Real FX, Delannoy P, Zweibaum A. GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells. J Cell Biol 1998;141:1311-22.
52. Delannoy P, Kim I, Emery N, De Bolos C, Verbert A, Degand P, Huet G. Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. Glycoconj J 1996;13:717-26.
53. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 2002;99: 568-73.